The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation

Biochemical Pharmacology

Volumn 76, Issue 9, 2008, Pages 1097-1109

  Cox, Andrew G ^a   Brown, Kristin K ^a   Arner, Elias S J ^b   Hampton, Mark B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Mitochondria; Peroxiredoxin; Thiols; Thioredoxin reductase

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; AURANOFIN; CYTOCHROME C; PEROXIREDOXIN; PEROXIREDOXIN 3; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; SELENOPROTEIN; THIOREDOXIN REDUCTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CELL PROLIFERATION; CELL SECRETION; CELL STRAIN U937; DRUG TARGETING; EMBRYO; ENZYME METABOLISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; AURANOFIN; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TRANSFORMED; CELL PROLIFERATION; HUMANS; JURKAT CELLS; MICE; MICE, KNOCKOUT; MITOCHONDRIAL PROTEINS; OXIDATION-REDUCTION; PEROXIREDOXINS; THIOREDOXIN-DISULFIDE REDUCTASE; U937 CELLS;

EID: 53649092133     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.08.021     Document Type: Article

References (81)

1. Arnér E.S.J., and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267 (2000) 6102-6109
2. Nordberg J., and Arner E.S.J. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31 (2001) 1287-1312
3. Wood Z.A., Schroder E., Harris J.R., and Poole L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28 (2003) 32-40
4. Jones D.P. Disruption of mitochondrial redox circuitry in oxidative stress. Chem Biol Interact 163 (2006) 38-53
5. Wonsey D.R., Zeller K.I., and Dang C.V. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA 99 (2002) 6649-6654
6. Hattori F., Murayama N., Noshita T., and Oikawa S. Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J Neurochem 86 (2003) 860-868
7. Nonn L., Berggren M., and Powis G. Increased expression-of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 1 (2003) 682-689
8. Chang T.S., Cho C.S., Park S., Yu S.Q., Kang S.W., and Rhee S.G. Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem 279 (2004) 41975-41984
9. Aumann N., Wolf G., and Walther R. Mitochondrial peroxiredoxin III protects pancreatic beta cells against apoptosis. Diabetologia 48 (2005) A186-A190
10. Cox A.G., Pullar J.M., Hughes G., Ledgerwood E.C., and Hampton M.B. Oxidation of mitochondrial peroxiredoxin 3 during the initiation of receptor-mediated apoptosis. Free Radic Biol Med 44 (2008) 1001-1009
11. Brown K.K., Eriksson S.E., Arner E.S.J., and Hampton M.B. Mitochondrial peroxiredoxin 3 is rapidly oxidised in cells treated with isothiocyanates. Free Radic Biol Med 45 (2008) 494-502
12. Tanaka T., Hosoi F., Yamaguchi-Iwai Y., Nakamura H., Masutani H., Ueda S., et al. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J 21 (2002) 1695-1703
13. Nonn L., Williams R.R., Erickson R.P., and Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol 23 (2003) 916-922
14. Conrad M., Jakupoglu C., Moreno S.G., Lippl S., Banjac A., Schneider M., et al. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 24 (2004) 9414-9423
15. España L., Martín B., Aragüés R., Chiva C., Oliva B., Andreu D., et al. Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis. Am J Pathol 167 (2005) 1125-1137
16. Park J.H., Kim Y.S., Lee H.L., Shim J.Y., Lee K.S., Oh Y.J., et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 11 (2006) 269-275
17. Kinnula V.L., Lehtonen S., Sormunen R., Kaarteenaho-Wiik R., Kang S.W., Rhee S.G., et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196 (2002) 316-323
18. Choi J.H., Kim T.N., Kim S.Y., Baek S.H., Kim J.H., Lee S.R., et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22 (2002) 3331-3335
19. Mukhopadhyay S.S., Leung K.S., Hicks M.J., Hastings P.J., Youssoufian H., and Plon S.E. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. J Cell Biol 175 (2006) 225-235
20. Urig S., and Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 16 (2006) 452-465
21. Arnér E.S.J., Nakamura H., Sasada T., Yodoi J., Holmgren A., and Spyrou G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 31 (2001) 1170-1178
22. Hashemy S.I., Ungerstedt J.S., Avval F.Z., and Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281 (2006) 10691-10697
23. Lu J., Chew E.H., and Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 104 (2007) 12288-12293
24. Wang X.F., Zhang J.S., and Xu T.W. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol Appl Pharmacol 218 (2007) 88-95
25. Witte A.B., Anestal K., Jerremalm E., Ehrsson H., and Arner E.S.J. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39 (2005) 696-703
26. Finkelstein A.E., Walz D.T., Batista V., Mizraji M., Roisman F., and Misher A. Auranofin-new oral gold compound for treatment of rheumatoid-arthritis. Ann Rheum Dis 35 (1976) 251-257
27. Mirabelli C.K., Johnson R.K., Sung C.M., Faucette L., Muirhead K., and Crooke S.T. Evaluation of the in vivo antitumor-activity and in vitro cyto-toxic properties of auranofin, a coordinated gold compound, in murine tumor-models. Cancer Res 45 (1985) 32-39
28. Barnard P.J., and Berners-Price S.J. Targeting the mitochondrial cell death pathway with gold compounds. Coordin Chem Rev 251 (2007) 1889-1902
29. Tiekink E.R.T. Gold derivatives for the treatment of cancer. Crit Rev Oncol Hemat 42 (2002) 225-248
30. McKeage M.J. Gold opens mitochondrial pathways to apoptosis. Br J Pharm 136 (2002) 1081-1082
31. Gromer S., Arscott L.D., Williams C.H., Schirmer R.H., and Becker K. Human placenta thioredoxin reductase-isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273 (1998) 20096-20101
32. Rigobello M.P., Messori L., Marcon G., Cinellu M.A., Bragadin M., Folda A., et al. Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. J Inorg Biochem 98 (2004) 1634-1641
33. Iñarrea P., Moini H., Han D., Rettori D., Aguiló I., Alava M.A., et al. Mitochondrial respiratory chain and thioredoxin reductase regulate intermembrane Cu,Zn-superoxide dismutase activity: implications for mitochondrial energy metabolism and apoptosis. Biochem J 405 (2007) 173-179
34. Rigobello M.P., Folda A., Baldoin M.C., Scutari G., and Bindoli A. Effect of Auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Radic Res 39 (2005) 687-695
35. Rigobello M.P., Folda A., Dani B., Menabò R., Scutari G., and Bindoli A. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells. Eur J Pharmacol 582 (2008) 26-34
36. Rigobello M.P., Scutari G., Boscolo R., and Bindoli A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br J Pharm 136 (2002) 1162-1168
37. Rigobello M.P., Scutari G., Folda A., and Bindoli A. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem Pharm 67 (2004) 689-696
38. Thomson S.J., Cox A.G., Cuddihy S.L., Pullar J.M., and Hampton M.B. Inhibition of receptor-mediated apoptosis upon Bcl-2 overexpression is not associated with increased antioxidant status. Biochem Biophys Res Commun 375 (2008) 145-150
39. Arnér E.S.J., Zhong L.W., and Holmgren A. Preparation and assay of mammalian thioredoxin and thioredoxin reductase. Methods Enzymol 300 (1999) 226-239
40. Mukhopadhyay P., Rajesh M., Yoshihiro K., Haskó G., and Pacher P. Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem Biophys Res Commun 358 (2007) 203-208
41. Jayaraman S. Flow cytometric determination of mitochondrial membrane potential changes during apoptosis of T lymphocytic and pancreatic beta cell lines: comparison of tetramethylrhodamineethylester (TMRE), chloromethyl-X-rosamine (H2-CMX-Ros) and MitoTracker Red 580 (MTR580). J Immunol Methods 306 (2005) 68-79
42. Riccardi C., and Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protocols 1 (2006) 1458-1461
43. Nordberg J., Zhong L., Holmgren A., and Arnér E.S.J. Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J Biol Chem 273 (1998) 10835-10842
44. Loschen G., Flohé L., and Chance B. Respiratory chain linked H(2)O(2) production in pigeon heart mitochondria. FEBS Lett 18 (1971) 261-264
45. Yoo M.H., Xu X.M., Carlson B.A., Gladyshev V.N., and Hatfield D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281 (2006) 13005-13008
46. Yoo M.H., Xu X.M., Carlson B.A., Patterson A.D., Gladyshev V.N., and Hatfield D.L. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLOS One 2 (2007) e1112
47. Chew E.H., Lu J., Bradshaw T.D., and Holmgren A. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J 22 (2008) 2072-2083
48. Chen Y., Cai J., Murphy T.J., and Jones D.P. Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells. J Biol Chem 277 (2002) 33242-33248
49. Chen Y., Cai J., and Jones D.P. Mitochondrial thioredoxin in regulation of oxidant-induced cell death. FEBS Lett 580 (2006) 6596-6602
50. Zhang H., Go Y.M., and Jones D.P. Mitochondrial thioredoxin-2/peroxiredoxin-3 system functions in parallel with mitochondrial GSH system in protection against oxidative stress. Arch Biochem Biophys 465 (2007) 119-126
51. Lin S., Del Razo L.M., Styblo M., Wang C., Cullen W.R., and Thomas D.J. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol 14 (2001) 305-311
52. Carvalho C.M., Chew E.H., Hashemy S.I., Lu J., and Holmgren A. Inhibition of human thioredoxin system: a molecular mechanism of mercury toxicity. J Biol Chem 283 (2008) 11713-11723
53. Bragadin M., Scutari G., Folda A., Bindoli A., and Rigobello M.P. Effect of metal complexes on thioredoxin reductase and the regulation of mitochondrial permeability conditions. Ann N Y Acad Sci 1030 (2004) 348-354
54. Hansen J.M., Zhang H., and Jones D.P. Differential oxidation of thioredoxin-1, thioredoxin-2, and glutathione by metal ions. Free Radic Biol Med 40 (2006) 138-145
55. Rabilloud T., Heller M., Rigobello M.P., Bindoli A., Aebersold R., and Lunardi J. The mitochondrial antioxidant defence system and its response to oxidative stress. Proteomics 1 (2001) 1105-1110
56. Orrenius S. Reactive oxygen species in mitochondria-mediated cell death. Drug Metab Rev 39 (2007) 443-455
57. Zhang R., Al-Lamki R., Bai L., Streb J.W., Miano J.M., Bradley J., et al. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res 94 (2004) 1483-1491
58. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17 (1998) 2596-2606
59. Fujino G., Noguchi T., Takeda K., and Ichijo H. Thioredoxin and protein kinases in redox signaling. Semin Cancer Biol 16 (2006) 427-435
60. Hansen J.M., Zhang H., and Jones D.P. Mitochondrial thioredoxin-2 has a key role in determining tumor necrosis factor-alpha-induced reactive oxygen species generation, NF-kappa B activation, and apoptosis. Toxicol Sci 91 (2006) 643-650
61. Amrán D., Sánchez Y., Fernández C., Ramos A.M., de Blas E., Bréard J., et al. Arsenic trioxide sensitizes promonocytic leukemia cells to TNFalpha-induced apoptosis via p38-MAPK-regulated activation of both receptor-mediated and mitochondrial pathways. Biochim Biophys Acta 1773 (2007) 1653-1663
62. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005) 652-658
63. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434 (2005) 658-662
64. Tsujimoto Y., and Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 12 (2007) 835-840
65. Anestål K., and Arner E. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 278 (2003) 15966-15972
66. Anestål K., Prast-Nielsen S., Cenas N., and Arnér E.S. Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLOS One 3 (2008) 1846
67. Cassidy P.B., Edes K., Nelson C.C., Parsawar K., Fitzpatrick F.A., and Moos P.J. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis 27 (2006) 2538-2549
68. Watson W.H., Heilman J.M., Hughes L.L., and Spielberger J.C. Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation. Biochem Biophys Res Commun 368 (2008) 832-836
69. Sengupta R., Ryter S.W., Zuckerbraun B.S., Tzeng E., Billiar T.R., and Stoyanovsky D.A. Thioredoxin catalyzes the denitrosation of low-molecular mass and protein S-nitrosothiols. Biochemistry 46 (2007) 8472-8483
70. Benhar M., Forrester M.T., Hess D.T., and Stamler J.S. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 320 (2008) 1050-1054
71. Jellicoe M.M., Nichols S.J., Callus B.A., Baker M.V., Barnard P.J., Berners-Price S.J., et al. Bioenergetic differences selectively sensitize tumorigenic liver progenitor cells to a new gold(I) compound. Carcinogenesis 29 (2008) 1124-1133
72. Coronnello M., Mini E., Caciagli B., Cinellu M.A., Bindoli A., Gabbiani C., et al. Mechanisms of cytotoxicity of selected organogold(III) compounds. J Med Chem 48 (2005) 6761-6765
73. Rackham O., Nichols S.J., Leedman P.J., Berners-Price S.J., and Filipovska A. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: Implications for anticancer therapeutics targeted to mitochondria. Biochem Pharmacol 74 (2007) 992-1002
74. Caruso F., Villa R., Rossi M., Pettinari C., Paduano F., Pennati M., et al. Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines. Biochem Pharm 73 (2007) 773-781
75. Wang Y., He Q.Y., Sun R.W., Che C.M., and Chiu J.F. GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res 65 (2005) 11553-11564
76. Marzano C., Gandin V., Folda A., Scutari G., Bindoli A., and Rigobello M.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42 (2007) 872-881
77. Powis G., Mustacich D., and Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29 (2000) 312-322
78. Arnér E.S.J., and Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 16 (2006) 420-426
79. Kirkin V., Joos S., and Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644 (2004) 229-249
80. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
81. Kean W.F., and Kean I.R. Clinical pharmacology of gold. Inflammopharmacology 16 (2008) 112-125